Study of LW402 in Moderate-to-Severe Atopic Dermatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-11

Study Completion Date

2025-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis

NCT07193589

Atopic Dermatitis

NOT_YET_RECRUITING PHASE2

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT07220577

Atopic Dermatitis

RECRUITING PHASE2

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

NCT06931990

Atopic Dermatitis (AD)

NOT_YET_RECRUITING PHASE1/PHASE2

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT04162899

Atopic Dermatitis

COMPLETED PHASE2

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

NCT04975438

Dermatitis, Atopic

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of an up-to-4-week screening period, a 12-week double-blind treatment period and a 4-week safety follow-up period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis (AD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LW402 Low Dose

LW402 administered orally, BID (low dose)

Group Type EXPERIMENTAL

LW402

Intervention Type DRUG

LW402 tablets

LW402 Medium Dose

LW402 administered orally, BID (medium dose)

Group Type EXPERIMENTAL

LW402

Intervention Type DRUG

LW402 tablets

LW402 High Dose

LW402 administered orally, BID (high dose)

Group Type EXPERIMENTAL

LW402

Intervention Type DRUG

LW402 tablets

Placebo

LW402 placebo administered orally, BID

Group Type PLACEBO_COMPARATOR

LW402 placebo

Intervention Type DRUG

LW402 placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LW402

LW402 tablets

Intervention Type DRUG

LW402 placebo

LW402 placebo tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with AD for at least 12 months before Screening, with below requirements: 1) EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 at Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline

Exclusion Criteria

* Not enough washing-out period for previous therapy. Concurrent disease/status which may potentially affect the efficacy/safety judgement.

pregnancy. Other.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No